Evidence map›Paper›PMID 38918674›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2024

Relapse and Survival in Bladder Cancer Patients Undergoing microRNA-129 and microRNA-145 Assays.

Mostafa M M ELfieky, Mohamed Abd El Rahman, Aysam M Fayed, Zahraa Haleem Al-Qaim, Ahmed Khalid Aldhalmi, Eman Ae Badr, Amal Abdel Aziz, Gehan M A Ibrahim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mostafa M M ELfiekyMolecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Egypt.
Mohamed Abd El RahmanCollege of Pharmacy, Al-Mustaqbal University, Babylon, 51001, Iraq.
Aysam M FayedMolecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Egypt.
Zahraa Haleem Al-QaimDepartment of Anesthesia Techniques, Al-Mustaqbal University College, Iraq.
Ahmed Khalid AldhalmiCollege of Pharmacy, Al-Mustaqbal University, Babylon, 51001, Iraq.
Eman Ae BadrMedical Biochemistry and Molecular Biology, Faculty of Medicine, Menoufia University, Egypt.
Amal Abdel AzizMolecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Egypt.
Gehan M A IbrahimMolecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe lack of indicators to measure tumor's invasive biological behavior is an important issue. The aim of this study was to examine the effect of miRNAs 129 and 145 on tumor progression as well as patient survival.

methodSeventy five breast cancer (BC) patients and 75 controls were included in this research. Two miRNA expressions were estimated using real-time PCR. Biomarkers for BC detection was tested using ROC curves and AUC.

resultmiR-129 and miR-145 expressions were significant. miR-129 and miR-145 classifiers (AUC = 0.943 and 0.748, respectively) help diagnose BC. Unlike miR-145, miR-129 did not affect the Kaplan-Meier survival curve analysis for progression-free survival at the end of the trial. The development of transitional cell carcinoma disease was found to have a strong correlation with miR-145 in both univariate and multivariate Cox regression analyses. Additionally, infiltrating + invasive urothelial carcinoma was also found to be correlated with miR-145. Conversely, elevated miR-129 expression in BC patients did not lead to an increase in cancer-specific recurrence or mortality, as observed in both univariate and multivariate Cox regression studies.

conclusionThe miRNA signature can help detect survival-associated miRNAs and develop BC miRNA therapeutics.

Indexed as

Biomarkers, TumorMicroRNAsNeoplasm Recurrence, LocalUrinary Bladder NeoplasmsAgedCarcinoma, Transitional CellCase-Control StudiesFemaleFollow-Up StudiesHumansMaleMiddle AgedPrognosisROC CurveSurvival RateBiomarkers, TumorMicroRNAsMirn129 microRNA, humanMIRN145 microRNA, humanbladder cancermicro145microRNA 129Relapsesurvival

Identifiers

PMID38918674
PMCPMC11382840

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.